Sacramento Business Journal - by Kathy Robertson, Staff writer
Date: Thursday, June 2, 2011, 1:22pm PDT
The Rancho Cordova-based company’s Res-Q system is designed to prepare cell concentrates. The first application was to process stem cells from bone marrow. A slightly modified version allows preparation of platelet-rich plasma.
“This represents a major regulatory milestone for the company and a key element of our product line extension strategy,” chairman and chief executive officer J. Melville Engle said in a statement.
The company has one distribution agreement in place for the new use and is in discussions with other potential partners, Engle said.
ThermoGenesis (Nasdaq: KOOL) provides technology to hospitals and blood banks that help in stem cell separation and preservation.
Company stock was trading at $2.18 midday Thursday. The 52-week high was $3.65 in January; the low, $1.60 in July.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.